Outlook Therapeutics, Inc. (OTLK)
NASDAQ: OTLK · Real-Time Price · USD
2.130
+0.040 (1.91%)
At close: Aug 13, 2025, 4:00 PM
2.040
-0.090 (-4.23%)
Pre-market: Aug 14, 2025, 9:25 AM EDT
Outlook Therapeutics Employees
Outlook Therapeutics had 23 employees as of September 30, 2024. The number of employees decreased by 1 or -4.17% compared to the previous year.
Employees
23
Change (1Y)
-1
Growth (1Y)
-4.17%
Revenue / Employee
n/a
Profits / Employee
$918,299
Market Cap
91.28M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
OTLK News
- 1 hour ago - Outlook Therapeutics Reports Financial Results for Third Quarter Fiscal Year 2025 and Provides Corporate Update - GlobeNewsWire
- 21 days ago - Outlook Therapeutics to Present at the 8th Annual Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase - GlobeNewsWire
- 23 days ago - Outlook Therapeutics Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference - GlobeNewsWire
- 6 weeks ago - Outlook Therapeutics Appoints Biopharmaceutical Industry and Commercial Leader Bob Jahr as Chief Executive Officer - GlobeNewsWire
- 2 months ago - Outlook Therapeutics to Participate in a Virtual Investor Lunch Break Event - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Announces SMC Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the Treatment of Wet AMD - GlobeNewsWire
- 2 months ago - Outlook Therapeutics® Announces Pricing of $13.0 Million Public Offering - GlobeNewsWire